IDXX Net income
Net income at Idexx Laboratories rose to $1.1B in fiscal 2025, the highest in the 5 years reported, from $888M in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 874716 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$1.1B
FY2024 $888M
HIGH$1.1B FY2025
LOW$679M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $1.1B | +$172M |
| FY2024 | $888M | +$43M |
| FY2023 | $845M | +$166M |
| FY2022 | $679M | $-66M |
| FY2021 | $745M | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · IDXX company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.